Last reviewed · How we verify
Denosumab treatment in osteoporotic patients
Denosumab treatment in osteoporotic patients is a Small molecule drug developed by Shinshu University. It is currently FDA-approved.
At a glance
| Generic name | Denosumab treatment in osteoporotic patients |
|---|---|
| Sponsor | Shinshu University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study on the Intervention Effect of Denosumab on High-Risk Patients With Osteoporotic Fractures in Type 2 Diabetes (NA)
- Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture (NA)
- Study Evaluating Denosumab on Bone and Vascular Metabolism in Osteoporotic Chronic Kidney Disease (PHASE4)
- Denosumab vs Alendronate After Vertebroplasty (NA)
- Denosumab vs Zoledronate After Vertebroplasty (PHASE4)
- Study Evaluating Denosumab on Vascular and Bone Metabolism in Osteoporotic Chronic Kidney Disease (HDENOBS)
- Efficacy of Denosumab Treatment in Bisphosphonate Unresponsive Patients
- Osteoporosis Treatment Protocol in Patients With Fragility Fractures: Application and Efficacy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Denosumab treatment in osteoporotic patients CI brief — competitive landscape report
- Denosumab treatment in osteoporotic patients updates RSS · CI watch RSS
- Shinshu University portfolio CI
Frequently asked questions about Denosumab treatment in osteoporotic patients
What is Denosumab treatment in osteoporotic patients?
Denosumab treatment in osteoporotic patients is a Small molecule drug developed by Shinshu University.
Who makes Denosumab treatment in osteoporotic patients?
Denosumab treatment in osteoporotic patients is developed and marketed by Shinshu University (see full Shinshu University pipeline at /company/shinshu-university).
What development phase is Denosumab treatment in osteoporotic patients in?
Denosumab treatment in osteoporotic patients is FDA-approved (marketed).